Bruce Blazar, MD, University of Minnesota
Leslie Kean, MD, PhD, Harvard University
Geneva National Resort
1221 Geneva National Avenue, South
Lake Geneva, WI 53147
Meeting #: Refer to your packet.
Hours: 8:00am – 8:00 pm EST M-F
International : 623-516-6140
Allogeneic Hematopoietic Cell Transplantation (HCT) represents a powerful curative therapy for a broad range of both malignant and non-malignant diseases. However, alongside its powerful disease-modifying and graft-versus-leukemia effects, allogeneic HCT is also associated with multiple toxicities, which continue to significantly compromise long-term success. Amongst the most deadly of these complications are acute and chronic GVHD, which together develop in up to 80% of HCT patients. This conference will identify the new horizons in the biology and therapeutics for GVHD. We will look deeply into the growing molecular understanding of the pathogenesis of this disease and develop an agenda for the key questions the field must address in order to eliminate this deadly complication of HCT. Importantly, the identification of underlying mechanisms and therapeutic strategies to control GVHD is expected to have wide relevance to a number of diseases and therapeutic modalities, including the fields of autoimmunity and of T cell-based immunotherapy strategies.
|Bruce Blazar, MD||University of Minnesota|
|Ronjon Chakraverty||Professor of Haematology and Cellular Immunotherapy|
|Coleen Delaney, PhD||Fred Hutchinson Cancer Research Center|
|John Dipersio, MD, PhD||Washington University School of Medicine in St. Louis|
|Jarrod Dudakov, PhD||Fred Hutchinson Cancer Research Center|
|Shernan Holtan, MD||University of Minnesota|
|Leslie Kean, MD, PhD||Boston Children's Hospital|
|Megan Levings, PhD||The University of British Columbia|
|Leo Luznik, MD||Johns Hopkins Medicine|
|Kelli Macdonald, PhD||Queensland Institute of Medical Research, Brisbane, Australia|
|Rob Negrin, MD||Stanford University|
|Pavan Reddy, MD||Roger Cancer Center, Michigan Medicine|
|Maria Roncarolo, MD||Stanford - Department of Pediatrics -- Ped Sted Cel Transplantation|
|Gerard Socie, MD, PhD||Hospital St. Louis in Paris|
|Robert Soiffer, MD||Dana-Farber Cancer Institute|
|Megan Sykes, MD||Columbia University|
|Marcel Van Den Brink, MD||Memorial Sloan Kettering Cancer Center|
|Robert Zeiser||University of Medical Center Freiburg (Germany)|
|J.C. Zúñiga-Pflücker, PhD||University of Toronto|
|Melinda Biernacki, MD||Fred Hutchinson Cancer Research Center|
|Tae Kon Kim||Vanderbilt University Medical Center|
|Armin Rashidi, MD, PhD||University of Minnesota, Division of Hematology, Oncology, and Transplantation|
Milwaukee's General Mitchell International Airport (MKE) is the preferred airport as it is only 45 minutes from the meeting location.
Chicago's O'Hare Airport (ORD) is 1 1/2 hours from the meeting location without traffic. The Foundation can only accommodate 1 pick up per day at O'Hare. If you absolutely must fly into O'Hare (ie: International Flights) the Foundation will have the following pick up times at O'Hare:
Any other arrival times at Chicago's O'Hare airport must be arranged and paid for by the individual. You are welcome to arrive on Wednesday.
The abstracts should be only one or two paragraphs outlining the theme of your presentation and should reflect the objective and spirit of the meeting (see above). Abstracts will be circulated about one week before the meeting. The meeting organizer will start requesting them a month before the meeting.
For more than 30 years, the Forbeck Foundation has proven to be an excellent steward of donor funds and has remained focused on executing its mission. Interested in sponsoring this Forum? Contact us today for more information!